Handelsavisen
prelaunch
Companies ›Consumer Non Cyclicals ›DMVF3.SA
DM
DMVF3.SA — B3 (São Paulo) Drug Retailers

Dmvf3.Sa

$7,07
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
3,1 %
ROE
2,5 %
Net margin
0,8 %
Debt / equity
0,52
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

DMVF3.SA operates in the drug retailing segment of the consumer non-cyclicals sector, generating revenue primarily through the sale of pharmaceuticals and related products.

Business. DMVF3.SA operates in the drug retailing segment of the consumer non-cyclicals sector, generating revenue primarily through the sale of pharmaceuticals and related products.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryDrug Retailers
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
2,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning DMVF3.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to DMVF3.SA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    DMVF3.SA operates in the drug retailing segment of the consumer non-cyclicals sector, generating revenue primarily through the sale of pharmaceuticals and related products.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryDrug Retailers
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    The company maintains a moderate liquidity position, with a current ratio of 1.08 and a debt-to-equity ratio of 0.52, indicating a balanced capital structure. However, the company's net cash position is negative after accounting for total debt, signaling potential liquidity constraints.

    Profitability metrics show a return on equity of 2.45% and a return on assets of 1.16%, which are below the typical thresholds for strong performance in the drug retailing industry. The company's operating income of 83,894,000 BRL and net income of 22,565,000 BRL reflect a relatively modest profit margin.

    Geographically and segment-wise, the company's revenue concentration is not disclosed, but the drug retailing industry is typically characterized by a mix of regional and national operations. The company's revenue of 2,666,765,000 BRL is derived from a broad range of products and services.

    The company's growth trajectory is modest, with a current revenue of 2,666,765,000 BRL and an analyst estimate of 2,160,645,000 BRL for the last actual revenue. This suggests a potential decline in revenue, which could impact future profitability.

    Risk factors include a medium liquidity risk and a low dilution risk. The company's capital structure and financial leverage are within acceptable limits, but the negative net cash position after debt is a concern. No significant dilution sources are identified, and the dilution risk is assessed as low.

    Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financial performance and risk profile remain stable, with no significant deviations from historical trends.

    Key takeaways
    • The company has a balanced capital structure with a debt-to-equity ratio of 0.52.
    • Profitability metrics are below typical thresholds for the drug retailing industry.
    • The company's liquidity position is moderate, with a current ratio of 1.08.
    • The company's revenue is derived from a broad range of products and services.
    • The company's growth trajectory is modest, with a potential decline in revenue.
    • Risk factors include a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $7,07
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $919.3M
    Net cashⓘ
    -$435.0M
    Current ratioⓘ
    1.1
    Debt / equityⓘ
    0.5
    ROAⓘ
    1.2%
    ROEⓘ
    2.5%
    Cash conversionⓘ
    732.0%
    CapEx / revenueⓘ
    -3.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin3,1 %Above median
    Net Margin0,9 %Below median
    ROE2,5 %Below median
    Capex / Rev-3,5 %Bottom quartile
    D/E0,52Below median
    Cash Conv7,32Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • DMVF3.SA Market data — financials · 2026-05-27
    • d1000 Varejo Farma Participacoes SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    DMVF3.SACanonical
    B3 (São Paulo) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage